Pfizer Contraceptive Tied To Brain Tumors

Contraceptives and medications on blue background
Photo: ADragan / Shutterstock

Regulators in multiple countries now warn that long-term, high-dose Depo-Provera use is linked to a higher risk of brain tumors called meningiomas, and the product information has been updated to reflect it.

Story Snapshot

  • A large national study found a higher meningioma risk with prolonged injectable medroxyprogesterone acetate use.
  • United Kingdom regulators issued formal risk warnings and label changes for high-dose products.
  • Pfizer’s own labeling acknowledges meningioma reports with long-term use and advises monitoring.
  • Officials say the absolute risk is very small, but the risk rises with dose and duration.

What the new evidence shows about risk

Researchers using national health data reported that prolonged use of injectable medroxyprogesterone acetate, the drug in Depo-Provera, was linked to a higher risk of intracranial meningioma. The study found an odds ratio of 5.55 for the 150 milligrams per 3 milliliters injection among long-term users, based on 9 exposed cases among 18,061 cases and 11 among 90,305 controls. The pattern points to higher risk with longer use. The European regulator later echoed this wording in standardized label text using the same figures.

The United Kingdom’s Medicines and Healthcare products Regulatory Agency issued a direct communication to clinicians. It warned about a small increased risk of meningioma with high-dose medroxyprogesterone acetate, including the injection. It said the excess risk seems driven by three years or more of use and advised steps to reduce exposure where possible. The same communication emphasized that, while relative risk rises, the absolute risk remains very small for most users.

How regulators and Pfizer changed the guidance

Following the study and reviews, regulators ordered changes to product information and patient materials. The United Kingdom communication limited new recommendations to high-dose products, not to lower doses under 100 milligrams or to combination medicines, signaling a focus on cumulative exposure. New Zealand’s medicines regulator described meningioma as a newly identified, very rare side effect, and it reported label updates that require stopping the drug if a meningioma occurs.

Pfizer’s own prescribing information for both Depo-Provera CI and depo-subQ provera states that meningiomas have been reported after repeated administration, mainly with long-term use. The labels direct clinicians to monitor for signs and symptoms and to discontinue if a patient is diagnosed with a meningioma. This language aligns with the risk-minimization steps regulators are now highlighting for prolonged, high-dose exposure.

What this means for patients, clinicians, and trust

Patients using Depo-Provera should talk with their clinicians about how long they have used it, the dose received, and any new symptoms such as headaches, vision changes, or seizures. Clinicians should reassess the need for continued high-dose, long-term use and consider alternatives when appropriate. Regulators state that benefits can still outweigh risks for many patients, but they ask providers to reduce exposure length and dose where feasible.

This episode feeds a broader frustration that safety issues surface late and that warnings change only after years of use. People on the right and left see a pattern: powerful institutions act slowly, and everyday families carry the risk. Here, the core facts are clear and narrow. A specific contraceptive at high doses over long periods is linked with a higher meningioma risk. The proper response is targeted: clear warnings, shared decision-making, and transparent data so patients are not kept in the dark.

Sources:

brainstrust.org.uk, itv.com, news.stv.tv, labeling.pfizer.com, medsafe.govt.nz, medicines.org.uk